Summary Protocol for a Multi-Centre Randomised Controlled Trial of Enteral Lactoferrin Supplementation in Newborn Very Preterm Infants (ELFIN): The ELFIN Trial Investigators Group

Neonatology

Volumn 114, Issue 2, 2018, Pages 142-148

  McGuire, William ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Infection; Lactoferrin; Preterm infants

Indexed keywords

LACTOFERRIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DRUG DISTRIBUTION; ECONOMIC EVALUATION; ENTERAL DRUG ADMINISTRATION; FOLLOW UP; HUMAN; INFECTION; INFORMED CONSENT; LATE ONSET INVASIVE INFECTION; MULTICENTER STUDY; NEWBORN; OUTCOME ASSESSMENT; PREMATURITY; PRIORITY JOURNAL; UNITED KINGDOM; COST BENEFIT ANALYSIS; DEVELOPMENTAL DISORDER; DIETARY SUPPLEMENT; ECONOMICS; ENTERIC FEEDING; FEMALE; GESTATIONAL AGE; INFANT; INFANT MORTALITY; LUNG DYSPLASIA; MALE; MULTICENTER STUDY (TOPIC); NECROTIZING ENTEROCOLITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY LOW BIRTH WEIGHT;

BRONCHOPULMONARY DYSPLASIA; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DEVELOPMENTAL DISABILITIES; DIETARY SUPPLEMENTS; ENTERAL NUTRITION; ENTEROCOLITIS, NECROTIZING; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT MORTALITY; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INFANT, VERY LOW BIRTH WEIGHT; LACTOFERRIN; MALE; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85048533240     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000488927     Document Type: Article

References (15)

1. Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011; 96:F9-F14.
2. Shane AL, Sánchez PJ, Stoll BJ: Neonatal sepsis. Lancet 2017; 390: 1770-1780.
3. Bassler D, Stoll BJ, Schmidt B, Asztalos EV, Roberts RS, Robertson CM, et al. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009; 123: 313-318.
4. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP: Lactoferrin: antimicrobial activity and therapeutic potential. Semin Fetal Neonatal Med 2013; 18: 143-149.
5. Ochoa TJ, Cleary TG: Effect of lactoferrin on enteric pathogens. Biochimie 2009; 91: 30-34.
6. Valenti P, Antonini G: Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 2005; 62: 2576-2587.
7. Legrand D, Pierce A, Elass E, Carpentier M, Mariller C, Mazurier J: Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606: 163-194.
8. González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q: Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33: 301.e1-e8.
9. Tian H, Maddox IS, Ferguson LR, Shu Q: Influence of bovine lactoferrin on selected probiotic bacteria and intestinal pathogens. Biometals 2010; 23: 593-596.
10. Actor JK, Hwang SA, Kruzel ML: Lactoferrin as an immune modulator. Curr Pharm Des 2009; 15: 1956-1973.
11. Buccigrossi V, de Marco G, Bruzzese E, Ombrato L, Bracale I, Polito G, et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007; 61: 410-414.
12. Raghuveer TS, McGuire EM, Martin SM, Wagner BA, Rebouché CJ, Buettner GR, et al. Lactoferrin in the preterm infants' diet attenuates iron-induced oxidation products. Pediatr Res.2002; 52: 964-972.
13. Vorland LH, Ulvatne H, Andersen J, Haukland H, Rekdal O, Svendsen JS, et al. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 1998; 30: 513-517.
14. Yamauchi K, Toida T, Nishimura S, Nagano E, Kusuoka O, Teraguchi S, et al. 13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. Food Chem Toxicol 2000; 38: 503-512.
15. Pammi M, Suresh G: Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2017; 6: CD007137.